CPT1A and malignant colon neoplasm: Blocking CPT1A with iRGD‐exo‐si sensitized cells to oxaliplatin with low toxicity and high tumour‐targeting ability, which not only provided an effective approach to treat colon cancer that is oxaliplatin resistant but also propelled the application of siRNA in the clinic.